632 related articles for article (PubMed ID: 15601443)
1. PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology.
Lees P; Giraudel J; Landoni MF; Toutain PL
J Vet Pharmacol Ther; 2004 Dec; 27(6):491-502. PubMed ID: 15601443
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics and pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest.
Lees P; Landoni MF; Giraudel J; Toutain PL
J Vet Pharmacol Ther; 2004 Dec; 27(6):479-90. PubMed ID: 15601442
[TBL] [Abstract][Full Text] [Related]
3. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine.
Toutain PL; Lees P
J Vet Pharmacol Ther; 2004 Dec; 27(6):467-77. PubMed ID: 15601441
[TBL] [Abstract][Full Text] [Related]
4. Principles of pharmacodynamics and their applications in veterinary pharmacology.
Lees P; Cunningham FM; Elliott J
J Vet Pharmacol Ther; 2004 Dec; 27(6):397-414. PubMed ID: 15601436
[TBL] [Abstract][Full Text] [Related]
5. Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis.
Lepist EI; Jusko WJ
J Vet Pharmacol Ther; 2004 Aug; 27(4):211-8. PubMed ID: 15305849
[TBL] [Abstract][Full Text] [Related]
6. Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations.
Goltsov A; Maryashkin A; Swat M; Kosinsky Y; Humphery-Smith I; Demin O; Goryanin I; Lebedeva G
Eur J Pharm Sci; 2009 Jan; 36(1):122-36. PubMed ID: 19028575
[TBL] [Abstract][Full Text] [Related]
7. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
Meibohm B; Derendorf H
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib.
Giraudel JM; Toutain PL; King JN; Lees P
J Vet Pharmacol Ther; 2009 Feb; 32(1):31-40. PubMed ID: 19161453
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors.
Huntjens DR; Danhof M; Della Pasqua OE
Rheumatology (Oxford); 2005 Jul; 44(7):846-59. PubMed ID: 15855183
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a new model of inflammation in the cat and selection of surrogate endpoints for testing anti-inflammatory drugs.
Giraudel JM; Diquelou A; Lees P; Toutain PL
J Vet Pharmacol Ther; 2005 Jun; 28(3):275-85. PubMed ID: 15953201
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.
McKellar QA; Sanchez Bruni SF; Jones DG
J Vet Pharmacol Ther; 2004 Dec; 27(6):503-14. PubMed ID: 15601444
[TBL] [Abstract][Full Text] [Related]
12. Use of a pharmacokinetic/pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib.
Giraudel JM; King JN; Jeunesse EC; Lees P; Toutain PL
J Vet Pharmacol Ther; 2009 Feb; 32(1):18-30. PubMed ID: 19161452
[TBL] [Abstract][Full Text] [Related]
13. Clinical interpretation of pharmacokinetic and pharmacodynamic data in zoologic companion animal species.
Kukanich B
Vet Clin North Am Exot Anim Pract; 2011 Jan; 14(1):1-20. PubMed ID: 21074699
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic/pharmacodynamic modelling of NSAIDs in a model of reversible inflammation in the cat.
Giraudel JM; Diquelou A; Laroute V; Lees P; Toutain PL
Br J Pharmacol; 2005 Nov; 146(5):642-53. PubMed ID: 16113689
[TBL] [Abstract][Full Text] [Related]
15. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic of cyclooxygenase inhibitors in humans.
Capone ML; Tacconelli S; Di Francesco L; Sacchetti A; Sciulli MG; Patrignani P
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):85-94. PubMed ID: 17164136
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and pharmacodynamic modelling of marbofloxacin administered alone and in combination with tolfenamic acid in goats.
Sidhu PK; Landoni MF; Aliabadi FS; Lees P
Vet J; 2010 May; 184(2):219-29. PubMed ID: 19299172
[TBL] [Abstract][Full Text] [Related]
18. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study.
King JN; Rudaz C; Borer L; Jung M; Seewald W; Lees P
Res Vet Sci; 2010 Jun; 88(3):497-506. PubMed ID: 20004922
[TBL] [Abstract][Full Text] [Related]
19. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.
Beretta C; Garavaglia G; Cavalli M
Pharmacol Res; 2005 Oct; 52(4):302-6. PubMed ID: 15939622
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
